use
nucleic
acid
na
amplif
techniqu
transform
diagnosi
viral
infect
central
nervou
system
cn
enhanc
sensit
method
enabl
detect
even
low
amount
viral
genom
cerebrospin
fluid
follow
year
experi
polymeras
chain
reaction
nabas
amplif
techniqu
nowaday
perform
diagnost
laboratori
becom
test
choic
diagnosi
sever
viral
cn
infect
herp
enceph
enteroviru
mening
viral
infect
occur
human
immunodefici
virusinfect
person
furthermor
use
establish
viral
etiolog
neurolog
syndrom
dubiou
origin
recognis
unusu
poorli
characteris
cn
diseas
quantit
method
provid
valuabl
addit
tool
clinic
manag
diseas
wherea
postamplif
techniqu
enabl
precis
genom
characteris
current
effort
aim
improv
diagnost
effici
molecular
techniqu
speed
standardis
reduc
cost
relev
na
amplif
strategi
clinic
applic
date
object
review
cerebrospin
fluid
csf
examin
essenti
part
diagnost
workup
patient
suspect
central
nervou
system
cn
viral
infect
often
mean
achiev
etiolog
diagnosi
either
direct
identif
respons
viru
demonstr
intrathec
specif
immun
respons
tradit
direct
virolog
techniqu
includ
viru
isol
antigen
detect
microscopi
examin
usual
low
sensit
viru
isol
cell
cultur
may
valu
diagnosi
asept
mening
enterovirus
found
almost
half
case
viru
isol
howev
insensit
virus
herp
simplex
viru
type
arbovirus
viru
antigen
detect
techniqu
light
electron
microscopi
limit
valu
requir
high
number
csfinfect
cell
viru
identif
rubin
hand
indirect
diagnosi
detect
intrathec
produc
antibodi
gener
poor
sensit
earli
stage
diseas
last
decad
nucleic
acid
na
amplificationbas
techniqu
primarili
polymeras
chain
reaction
pcr
revolutionis
diagnosi
cn
infect
especi
caus
virus
fredrick
relman
advantag
account
success
diagnost
neurovirolog
extraordinari
sensit
rapid
techniqu
first
appli
csf
earli
diagnosi
herp
simplex
enceph
hse
enterovir
mening
et
al
rotbart
sinc
number
scientif
report
field
rapidli
increas
na
amplificationbas
assay
routin
perform
diagnost
laboratori
na
amplificationbas
techniqu
becom
test
choic
viral
cn
infect
hse
darnel
tyler
weber
et
al
cinqu
et
al
furthermor
use
establish
viral
etiolog
neurolog
syndrom
dubiou
origin
eg
mollaret
mening
tedder
et
al
help
recognis
unusu
poorli
characteris
cn
diseas
mild
form
herp
enceph
schlesing
et
al
devincenzo
thorn
domingu
et
al
fodor
et
al
cytomegaloviru
cmv
ventriculoenceph
human
immunodefici
viru
hiv
infect
patient
arriba
et
al
molecular
method
made
possibl
identifi
virus
csf
normal
caus
extracerebr
infect
rotaviru
parvoviru
cmv
human
herpesviru
thu
support
etiolog
role
induc
cn
diseas
kondo
et
al
suga
et
al
cassinotti
et
al
ushijima
et
al
studahl
et
al
mcculler
et
al
barah
et
al
final
molecular
techniqu
uniqu
valu
identif
novel
virus
respons
cn
diseas
chua
et
al
cardosa
et
al
method
csf
treatment
usual
requir
prior
na
amplif
order
releas
na
cell
remov
substanc
may
degrad
na
inhibit
amplif
howev
rel
simpl
csf
composit
may
obviat
least
dna
virus
need
na
purif
simplest
approach
includ
heat
high
temperatur
repeat
freezethaw
specimen
procedur
facilit
cell
membran
disrupt
releas
dna
tabl
procedur
advantag
rapid
requir
small
csf
volum
reduc
risk
sampl
contamin
na
purif
step
howev
lack
remov
inhibit
molecul
might
interfer
tabl
csf
prepar
prior
nucleic
acid
amplif
principl
method
exampl
csf
cell
lysi
heat
freez
thaw
csf
cell
lysisprotein
digest
deterg
sd
proteas
proteas
k
chaotropioc
agent
guanidiniun
thiocyan
nuclic
acid
concentr
ultracentrifug
ethanol
precipit
nucleic
acid
nucleic
acid
extract
phenol
spin
column
silic
absorpt
magnet
separ
method
cell
lysi
concentr
extract
nucleic
acid
variabl
combin
requir
time
vari
min
eg
mechan
cell
lysi
h
eg
proteas
k
digest
andor
complex
nucleic
acid
procedur
eg
phenol
requir
volum
vari
ml
eg
mechan
cell
lysi
ml
use
csf
concentr
procedur
enzym
use
amplif
na
may
also
concentr
andor
purifi
csf
number
inhous
procedur
commerci
kit
tabl
although
extract
method
seem
perform
better
other
compar
studi
casa
et
al
fahl
fischer
none
known
protocol
shown
clearli
superior
practic
choic
one
csf
prepar
method
support
number
consider
includ
type
na
target
amplif
protocol
employ
well
individu
laboratori
experi
na
amplif
techniqu
enabl
amplif
small
quantiti
target
na
molecul
consider
larger
amount
copi
visualis
mean
common
laboratori
procedur
result
high
sensit
main
advantag
techniqu
pcr
popular
amplif
method
number
techniqu
describ
includ
ligas
chain
reaction
strand
displac
assay
transcript
mediat
amplif
nucleic
acid
sequenc
base
amplif
nasba
branch
dna
techniqu
hybrid
captur
assay
pcr
wide
use
detect
csf
dna
rna
virus
case
rna
virus
complementari
dna
cdna
need
gener
rna
prior
amplif
mean
revers
transcriptas
rt
variant
classic
procedur
larg
use
analysi
csf
biolog
fluid
contain
viral
particl
nest
pcr
consist
two
separ
amplif
reaction
use
two
primer
set
second
locat
first
one
thu
increas
substanti
sensit
specif
detect
na
amplif
techniqu
pcr
appli
detect
viral
genom
csf
includ
nasba
branch
dna
assay
nasba
like
pcr
base
target
na
amplif
synthesi
new
molecul
occur
isotherm
reaction
requir
three
differ
enzym
furthermor
templat
consist
rna
kievit
et
al
exampl
nasba
studi
csf
includ
perform
detect
cmv
late
gene
transcript
hivinfect
patient
cmv
enceph
enteroviru
west
nile
wn
st
loui
enceph
viru
rna
patient
asept
mening
enceph
zhang
et
al
bestetti
et
al
lanciotti
kerst
heim
schumann
fox
et
al
assess
rna
level
patient
hiv
infect
differ
diseas
stage
mcarthur
et
al
shepard
et
al
branch
dna
assay
base
signal
amplif
rather
targetamplif
urdea
assay
use
measur
cmv
dna
rna
level
csf
hivinfect
patient
flood
et
al
stingel
et
al
differ
procedur
detect
product
na
amplif
simplest
techniqu
base
visualis
dna
band
expect
size
agaros
gel
electrophoresi
stain
ethidiumbromid
altern
support
method
includ
hybridis
dna
probe
complementari
target
dna
follow
dna
transfer
filter
tube
micropl
probe
label
enzym
molecul
lead
signal
detect
appropri
stimul
colorimetr
enzymelink
immunosorb
assay
elisa
amplifi
product
captur
probe
coat
micropl
prove
practic
reason
colorimetr
elisa
larg
adapt
commerci
kit
use
csf
analysi
number
virus
rotbart
et
al
elli
et
al
sinc
similar
neurolog
pictur
may
result
differ
cn
infect
may
practic
use
pcr
assay
detect
one
viru
infecti
agent
reaction
obviou
advantag
approach
number
test
reduc
substanti
time
cost
save
two
main
strategi
use
purpos
multiplex
pcr
pcr
consensu
primer
multiplex
pcr
enabl
identif
one
dna
sequenc
mean
two
primer
pair
specif
one
sequenc
fig
import
requir
approach
amplif
condit
ie
reagent
mixtur
composit
thermocycl
profil
similar
primer
pair
order
compromis
amplif
effici
primer
pair
develop
multiplex
pcr
might
lead
univers
diagnost
protocol
base
use
sever
primer
pair
fix
thermocycl
program
reagent
composit
kuno
multiplex
pcr
assay
larg
employ
diagnost
neurovirolog
eg
simultan
detect
kimura
et
al
cassinotti
et
al
cinqu
et
al
larger
number
herpesvirus
tenorio
et
al
baron
et
al
pozo
tenorio
quereda
et
al
markoulato
et
al
protocol
also
design
simultan
amplif
virus
caus
similar
clinic
pictur
includ
assay
herpesviru
enteroviru
read
kurtz
casa
et
al
measl
rubella
parvoviru
del
mar
mosquera
et
al
differ
combin
mosquitotransmit
virus
lee
et
al
duplex
pcr
protocol
amplif
epstein
viru
ebv
toxoplasma
gondii
also
propos
aid
patient
help
distinguish
cn
lymphoma
toxoplasmosi
robert
storch
pcr
consensu
primer
use
amplifi
conserv
sequenc
common
differ
virus
belong
famili
follow
amplif
product
may
identifi
dna
sequenc
hybridis
specif
probe
restrictionenzym
analysi
fig
possibl
visualis
band
differ
size
agaros
gel
strategi
wide
success
use
herpesvirus
amplifi
simultan
cmv
ebv
mean
primer
target
conserv
region
herpesviru
dna
polymeras
gene
rozenberg
lebon
detect
known
human
herpesvirus
two
pcr
assay
singl
reaction
use
stair
primer
minjol
et
al
bouquillon
et
al
exampl
includ
protocol
design
detect
enteroviru
strain
use
primer
recognis
conserv
sequenc
within
noncod
region
picornaviru
famili
kammer
et
al
three
human
polyomavirus
jc
viru
jcv
bk
viru
arthur
et
al
fedel
et
al
differ
flavivirus
harri
et
al
scaramozzino
et
al
mousavijazi
lundkvist
unpublish
observ
fig
exampl
multiplex
pcr
three
unrel
sequenc
vzv
amplifi
simultan
test
tube
use
three
differ
primer
pair
specif
viru
amplif
product
differenti
agaros
gel
amplifi
fragment
yield
band
differ
size
bp
dna
ladder
marker
altern
amplif
product
identifi
addit
step
hybrid
specif
probe
restrict
enzym
analysi
nest
pcr
specif
intern
primer
dna
sequenc
possibl
gener
fals
posit
result
sampl
contamin
major
risk
na
amplif
techniqu
clinic
specimen
product
previou
amplif
carryov
common
sourc
contamin
order
minim
risk
recommend
maintain
csf
steril
prelaboratori
laboratori
step
carri
differ
laboratori
step
separ
area
pers
addit
laboratori
use
enzym
uracil
n
glycosilas
ung
degrad
product
previou
amplif
nativ
na
templat
prevent
carryov
amplif
product
accomplish
substitut
dutp
dttp
amplif
mixtur
pretreat
subsequ
mixtur
ung
prior
amplif
longo
et
al
gener
use
neg
control
usual
water
known
neg
sampl
test
parallel
csf
specimen
throughout
whole
procedur
analysi
sampl
duplic
use
recognis
fals
posit
result
fals
neg
result
caus
presenc
inhibitor
ie
molecul
affect
correct
function
enzym
inhibit
amplif
report
csf
specimen
order
reveal
presenc
inhibit
may
use
amplifi
intern
standard
molecul
togeth
target
addit
amplif
rozenberg
lebon
conserv
dna
sequenc
polymeras
gene
ebv
cmv
amplifi
simultan
tube
consensu
primer
pair
target
region
common
virus
follow
agaros
gel
electrophoresi
amplifi
product
similar
length
top
viru
distinguish
use
restrict
enzym
bottom
sma
b
bam
hi
dna
marker
altern
virus
differenti
follow
hybrid
virusspecif
probe
dna
sequenc
strong
weak
posit
control
parallel
csf
sampl
help
monitor
amplif
effici
whole
reaction
sinc
viabl
viru
necessari
na
amplificationbas
procedur
na
found
csf
sampl
kept
store
long
period
dna
hsv
recov
csf
sampl
maintain
day
even
room
temperatur
wiedbrauk
cunningham
actual
recov
follow
storag
sever
year
person
observ
practic
point
view
consid
safe
send
csf
specimen
search
dna
virus
laboratori
room
temperatur
howev
prefer
csf
sampl
kept
even
shortterm
storag
frozen
deliv
examin
within
day
cinqu
et
al
hand
rna
regard
less
stabl
dna
detect
plasma
seem
affect
factor
type
anticoagul
use
specimen
collect
storag
temperatur
moudgil
daar
holodniy
et
al
howev
recoveri
enteroviru
rna
csf
seem
reduc
storag
room
temperatur
h
sampl
rotbart
et
al
similarli
signific
decay
rna
load
observ
h
storag
ahmad
et
al
theoret
storag
might
actual
advantag
case
envelop
rna
virus
freez
may
destroy
envelop
thu
make
rna
vulner
nucleas
tabl
show
overview
na
amplif
use
diagnost
immunocompet
immunocompromis
patient
respect
relev
exampl
briefli
emphasis
detect
dna
csf
one
convinc
exampl
diagnost
use
molecular
analysi
approach
larg
replac
identif
hsv
brain
tissu
biopsi
method
choic
etiolog
diagnosi
hse
lind
et
al
number
retrospect
prospect
studi
demonstr
reliabl
pcr
method
report
sensit
higher
virtual
specif
aureliu
et
al
lakeman
whitley
lind
et
al
furthermor
na
amplif
techniqu
enabl
diagnosi
uncommon
form
hsv
cn
infect
might
otherwis
go
unrecognis
schlesing
et
al
devincenzo
thorn
domingu
et
al
fodor
et
al
importantli
csf
analysi
techniqu
rapid
make
laboratori
diagnosi
use
manag
decis
howev
import
pcr
result
interpret
cautious
relat
clinic
present
durat
antivir
therapi
initi
neg
pcr
result
observ
earli
onset
hse
symptom
like
reflect
still
limit
viru
replic
rozenberg
lebon
ckl
et
al
hand
likelihood
find
posit
csf
pcr
result
reduc
follow
day
acyclovir
treatment
well
untreat
patient
csf
obtain
late
onset
neurolog
symptom
rozenberg
lebon
aureliu
et
al
lakeman
whitley
although
enterovirus
frequent
isol
csf
patient
enterovir
mening
cell
cultur
molecular
techniqu
significantli
improv
detect
rate
infect
jefferi
et
al
protocol
design
primer
recognis
almost
enteroviu
serotyp
includ
isol
cell
system
except
echo
virus
diverg
extrem
serotyp
oberst
et
al
enhanc
sensit
na
amplif
method
viru
also
detect
csf
sampl
obtain
day
onset
symptom
isol
viru
usual
infrequ
yerli
et
al
furthermor
aureliu
et
al
kimura
et
al
lakeman
whitley
lind
et
al
kimberlin
et
al
asept
mealaig
recurr
mening
neonat
infect
parvovirida
ssdna
asept
mening
etiolog
character
diagnosi
parvoviru
mening
cassinotti
et
al
okumura
ichikawa
druschki
et
al
barah
et
al
picronavirida
diagnost
potenti
detect
cellassoci
dna
kompol
et
al
furuya
et
al
cavroi
et
al
na
virus
also
found
csf
without
clear
associ
cn
diseas
eg
hepat
c
viru
hcv
ttv
coronaviru
maggi
et
al
dessau
et
al
cristallo
et
al
maggi
et
al
tognon
et
al
hcv
rna
also
found
csf
hivinfect
patient
without
clear
associ
cn
diseas
maggi
et
al
morsica
et
al
gazzola
et
al
pcnsl
primari
cn
lymphoma
see
tabl
footnot
use
techniqu
reduc
time
diagnosi
day
day
diagnost
reliabl
inhous
commerci
na
amplif
assay
extens
evalu
show
sensit
specif
compar
viral
isol
low
specif
probabl
reflect
enteroviru
detect
cultureneg
csf
sampl
patient
true
enteroviru
mening
glimak
et
al
lina
et
al
yerli
et
al
muir
van
loon
romero
although
highli
sensit
method
develop
detect
viral
genom
patient
sampl
import
arboand
rodentborn
virus
method
mani
case
limit
valu
routin
diagnost
major
reason
time
period
viremia
often
short
ie
viru
usual
longer
detect
onset
system
cn
diseas
typic
exampl
tickborn
enceph
tbe
attempt
use
rtpcr
tract
tbe
viru
rna
acut
phase
csf
serum
larg
extent
unsuccess
sampl
found
posit
seroneg
igmposit
iggneg
phase
nther
ckl
et
al
lundkvist
et
al
unpublish
observ
exampl
detect
viral
genom
limit
use
diagnost
base
least
supplement
serolog
japanes
enceph
igarachi
et
al
enceph
caus
western
eastern
venezuelan
equin
enceph
dengu
virus
hand
use
rtpcr
csf
render
posit
result
flavivirus
west
nile
viru
bunyavirus
eg
la
cross
jamestown
canyon
toscana
virus
realtim
pcr
analysi
csf
sampl
collect
patient
serolog
confirm
west
nile
enceph
epidem
new
york
area
reveal
sensit
specif
respect
lanciotti
et
al
although
correl
observ
posit
rate
surviv
observ
remain
confirm
bries
et
al
toscana
viru
phlebotomustransmit
viru
caus
endem
infect
tuscani
area
itali
respons
benign
form
mening
rtpcr
toscana
viru
sequenc
identifi
csf
mani
patient
acut
mening
hospitalis
geograph
area
find
indic
na
amplif
analysi
valid
diagnost
support
also
mean
estim
relev
diseas
popul
valassina
et
al
neurolog
complic
one
major
problem
patient
hiv
infect
although
frequenc
significantli
declin
develop
world
follow
advent
highli
activ
antiretrovir
therapi
haart
still
repres
major
diagnost
therapeut
challeng
cn
diseas
caus
virus
includ
enceph
mening
myeliti
mix
pictur
caus
herpesvirus
progress
multifoc
leukoencephalopathi
pml
associ
jcv
infect
cn
field
impact
diagnost
molecular
techniqu
remark
cinqu
et
al
detect
cmv
dna
csf
shown
highli
sensit
specif
diagnosi
cmv
enceph
diseas
report
mani
one
third
aid
patient
cinqu
et
al
gozlan
et
al
wolf
spector
clifford
et
al
fox
et
al
cinqu
et
al
identif
varicellazost
viru
dna
csf
larg
contribut
identifi
clinic
characteris
cn
complic
induc
virus
also
provid
use
tool
diagnosi
clinic
manag
tan
et
al
miller
et
al
burk
et
al
cinqu
et
al
cinqu
et
al
iten
et
al
csf
pcr
jcv
partli
replac
practic
brain
biopsi
diagnost
method
choic
pml
though
jcv
sequenc
demonstr
pcr
two
third
patient
higher
rate
detect
advanc
stage
diseas
weber
et
al
fong
et
al
mcguir
et
al
cinqu
et
al
de
luca
et
al
furthermor
clearanc
jcv
dna
csf
frequent
observ
patient
receiv
haart
associ
pml
stabilis
miral
et
al
giudici
et
al
suggest
rate
jcv
dna
detect
among
pml
patient
might
decreas
consequ
antihiv
therapi
anoth
virusrel
cn
diseas
hivinfect
patient
primari
cn
lymphoma
pcnsl
almost
alway
associ
presenc
ebv
tumour
cell
macmahon
et
al
studi
patient
histolog
proven
pcnsl
cn
local
system
nonhodgkin
lymphoma
report
strike
associ
presenc
complic
ebv
dna
detect
csf
patient
ebvdna
could
even
detect
day
month
lymphoma
manifest
clinic
cinqu
et
al
arriba
et
al
de
luca
et
al
cinqu
et
al
cingolani
et
al
measur
amount
na
clinic
specimen
success
develop
basic
diagnost
molecular
techniqu
pcr
na
amplif
techniqu
proven
reliabl
purpos
varieti
semiquantit
quantit
pcr
method
describ
clementi
et
al
hodinka
preiser
et
al
semiquantit
techniqu
includ
method
base
limit
dilut
sampl
amplif
comparison
extent
amplif
sampl
extern
standard
known
na
concentr
main
disadvantag
procedur
take
account
possibl
differ
amplif
effici
differ
sampl
andor
standard
quantit
techniqu
allow
accur
estim
na
level
coamplif
tube
target
na
intern
standard
known
concentr
enabl
control
amplif
effici
new
autom
procedur
base
realtim
detect
na
becom
popular
diagnost
neurovirolog
realtim
pcr
base
detect
quantif
fluoresc
report
fluoresc
emiss
record
cycl
make
possibl
monitor
pcr
reaction
exponenti
phase
amount
pcr
product
correl
initi
quantiti
templat
compar
classic
method
amount
dna
measur
end
amplif
amplif
effici
reduc
realtim
pcr
accur
expand
dynam
rang
quantif
also
elimin
postpcr
process
amplif
product
result
reduc
risk
contamin
increas
speed
bustin
two
gener
method
na
quantit
realtim
pcr
base
use
dnabind
dye
eg
syber
green
fluorescencelabel
probe
latter
employ
taqman
fig
holland
et
al
higuchi
et
al
heid
et
al
lightcycl
wittwer
et
al
b
technolog
describ
quantit
viral
dna
csf
kessler
et
al
verstrepen
et
al
gunther
et
al
nagai
et
al
read
et
al
gautheretdejean
et
al
aberl
ckl
tabl
realtim
pcr
also
allow
simultan
quantif
tube
differ
genom
read
et
al
well
viru
genotyp
mutat
analysi
quantif
viral
genom
csf
import
time
diagnosi
viral
enceph
mening
order
obtain
diagnost
prognost
inform
well
subsequ
patient
manag
eg
antivir
therapi
tabl
summaris
signific
clinic
applic
quantit
molecular
techniqu
viral
cn
infect
cmv
hiv
infect
cn
good
exampl
quantit
method
use
cmv
enceph
measur
csf
cmv
dna
level
time
diagnosi
use
order
distinguish
extens
mild
infect
arriba
et
al
bestetti
et
al
patient
cmv
enceph
polyradiculomyel
cmv
dna
level
tend
decreas
follow
antivir
therapi
ganciclovir
foscarnet
although
persist
signific
level
frequent
associ
lack
clinic
improv
cinqu
et
al
flood
et
al
commerci
assay
includ
pcr
nasba
bdna
assay
use
rna
quantif
csf
consequ
earli
viru
invas
cn
rna
detect
csf
stage
hiv
infect
irrespect
presenc
neurolog
symptom
howev
csf
viral
load
usual
higher
patient
product
hiv
infect
brain
cell
ie
hivassoci
dementia
enceph
mcarthur
et
al
brew
et
al
elli
et
al
cinqu
et
al
current
antihiv
treatment
induc
substanti
decreas
csf
rna
level
quantit
molecular
techniqu
thu
use
monitor
local
respons
treatment
gisslen
et
al
foudrain
et
al
stapran
et
al
gisolf
et
al
price
et
al
besid
use
direct
diagnosi
na
amplif
techniqu
constitut
base
genom
analysi
techniqu
yield
high
amount
genom
materi
analys
differ
purpos
includ
viru
characteris
epidemiolog
phylogenet
studi
detect
viral
mutat
eg
associ
antivir
drug
resist
neurotrop
neurovirul
addit
genotyp
virus
csf
may
use
recognis
unusu
viral
strain
characteris
new
viral
pathogen
involv
cn
diseas
fig
exampl
standard
curv
consist
ebv
dna
genomesreact
gener
autom
realtim
pcr
use
taqman
technolog
fluoresc
proport
amount
amplifi
product
acquir
pcr
cycl
autom
fluoromet
threshold
cycl
c
defin
cycl
number
fluoresc
pass
fix
threshold
quantif
amount
target
unknown
sampl
accomplish
measur
c
compar
valu
c
valu
standard
curv
number
postamplif
method
describ
recent
review
elsewher
aren
among
dna
sequenc
restrict
fragment
length
polymorph
rflp
hybridisationbas
techniqu
use
neurovirolog
nucleotid
sequenc
accur
method
collect
inform
genom
composit
autom
procedur
develop
recent
year
make
sequenc
rel
easi
perform
fig
rflp
restrict
enzym
use
digest
na
fragment
differ
size
visualis
gel
electrophoresi
techniqu
use
csf
pcr
consensu
primer
distinguish
individu
virus
viral
strain
fig
rozenberg
lebon
arthur
et
al
hybridisationbas
techniqu
includ
classic
procedur
southern
blot
well
modern
high
stringenc
hybridis
latter
identifi
minim
variat
genom
composit
singl
mutat
exampl
revers
hybridis
techniqu
incorpor
commerci
line
probe
assay
lipa
use
detect
hiv
resist
mutat
csf
plasma
pair
cunningham
et
al
dna
microarray
dna
chip
technolog
might
becom
addit
tool
identif
genom
analysi
viru
sequenc
amplifi
csf
peas
et
al
lockhart
winzel
mcglennen
despit
high
cost
current
limit
avail
technolog
instrument
dna
chip
technolog
rapid
develop
virolog
especi
field
research
eg
measur
viral
gene
express
chamber
et
al
jenner
et
al
sequenc
plasma
clinic
sampl
initi
test
epidemiolog
diagnost
purpos
screen
multipl
drug
resist
mutat
wilson
et
al
tabl
summaris
signific
applic
genotyp
analysi
neurovirolog
identif
enteroviru
strain
exampl
viru
genotyp
epidemiolog
clinic
purpos
molecular
type
enterovirus
may
use
epidemiolog
fig
dna
sequenc
pair
csf
plasma
specimen
exampl
nucleotid
sequenc
pair
csf
plasma
sampl
use
cyclesequenc
dyelabel
oligonucleotid
amplifi
product
obtain
pair
csf
plasma
specimen
follow
nucleic
acid
extract
rna
retrotranscript
pcr
amplif
fragment
revers
transcriptas
rt
gene
amplifi
dna
purifi
unincorpor
primer
nucleotid
ad
sequenc
reaction
mixtur
product
sequenc
reaction
subect
autom
electrophoresi
recogn
laser
scanner
fourcolor
electropherogram
produc
translat
linear
nucleotid
sequenc
comput
softwar
final
sequenc
compar
refer
sequenc
eg
three
nucleotid
mutat
result
two
aminoacid
substitut
codon
found
plasma
scf
arrow
mutat
associ
resist
rt
inhibitor
drug
zidovudin
rozenberg
lebon
tymidin
kinas
dna
sequenc
possibl
determin
neurovirul
found
surveil
programm
also
diagnost
prognost
signific
correctli
identifi
poliovirus
new
enteroviru
type
variant
enterovirus
respons
sever
infect
caus
infect
neonat
immunodefici
muir
et
al
molecular
type
system
enterovirus
might
becom
rapid
altern
tradit
serotyp
timeconsum
labourintens
requir
viru
isol
cell
cultur
muir
et
al
oberst
et
al
dna
sequenc
csf
enabl
diagnosi
cn
diseas
caus
attenu
vaccin
strain
rather
wildtyp
virus
exampl
mening
case
caus
urab
vaccin
mump
end
forsey
et
al
brown
et
al
recent
report
vaccineinduc
yellow
fever
case
martin
et
al
novel
cn
pathogen
identifi
follow
isol
andor
amplif
csf
recent
exampl
two
paramyxovirus
hendra
viru
transmit
hors
caus
mening
enceph
human
osullivan
et
al
nipah
viru
identifi
patient
enceph
outbreak
malaysia
singapor
chua
et
al
similarli
newli
describ
b
adenoviru
unexpectedli
identifi
molecular
techniqu
epidem
enteroviru
enceph
malaysia
cardosa
et
al
anoth
field
applic
postamplif
analys
pharmacogenom
term
indic
studi
genom
treatment
manag
one
signific
exampl
neurovirolog
studi
hiv
genom
mutat
select
antihiv
drug
schinazi
et
al
hirsch
et
al
drug
resist
viral
mutant
identifi
csf
infrequ
show
mutat
profil
differ
found
plasma
bodi
site
fig
cunningham
et
al
venturi
et
al
cinqu
et
al
stingel
et
al
find
might
provid
inform
concern
viral
dynam
differ
bodi
compart
might
also
use
clinic
manag
cn
hivinduc
complic
steuler
et
al
key
et
al
kuiken
et
al
env
dna
sequenc
identif
polymorph
possibl
associ
adc
power
et
al
di
stefano
et
al
rflp
restrict
fragment
length
polymorph
dgge
denatur
gradient
gel
electrophoresi
lipa
line
probe
assay
adc
aid
dementia
complex
pml
progress
multifoc
leukoencephalopathi
yf
yellow
fever
clear
use
molecular
techniqu
tremend
improv
diagnosi
clinic
manag
viral
cn
infect
hand
potenti
problem
relat
interpret
na
amplif
result
cost
standardis
techniqu
deserv
particular
consider
although
diagnost
valu
na
amplif
techniqu
well
establish
number
viral
cn
infect
hse
enteroviru
mening
opportunist
diseas
hivinfect
patient
still
unclear
less
frequent
encount
infect
exampl
enceph
caus
certain
zoonot
virus
complic
viral
exanthema
like
measl
rubella
tabl
viral
genom
occasion
found
csf
patient
infect
pcr
amplif
techniqu
howev
pauciti
case
studi
rate
detect
diseas
patient
control
clinic
signific
well
known
potenti
na
amplif
method
remain
mani
case
uncertain
infrequ
viral
na
found
csf
patient
infecti
noninfecti
cn
diseas
without
clear
caus
associ
diseas
frequent
observ
virus
may
latent
circul
blood
cell
brain
bodi
site
exampl
detect
ebv
csf
patient
diagnos
cn
infect
hse
hivrel
opportunist
infect
cinqu
et
al
tang
et
al
studahl
et
al
portolani
et
al
theoret
find
might
result
slide
viru
latent
infect
lymphocyt
impair
bloodcsf
barrier
also
reactiv
ebv
infect
cn
bossolasco
et
al
viral
genom
also
found
csf
patient
noninfecti
cn
diseas
instanc
jcv
genom
demonstr
patient
multipl
sclerosi
though
etiolog
role
diseas
never
confirm
ferrant
et
al
liedtk
et
al
instanc
viral
na
detect
csf
prior
onset
clinic
relev
neurolog
symptom
advantag
order
allow
earli
diagnosi
observ
aid
patient
viral
agent
eg
cmv
ebv
yet
caus
clinic
diseas
may
occasion
identifi
csf
patient
anoth
neurolog
complic
cinqu
et
al
exampl
consequ
extrem
sensit
na
amplif
techniqu
underlin
import
care
interpret
na
amplif
find
csf
within
individu
clinic
context
like
quantit
molecular
techniqu
might
help
discrimin
clinic
signific
infect
characteris
viral
replic
high
viral
load
incident
csf
find
elev
cost
potenti
disadvantag
csf
examin
na
amplif
techniqu
take
account
expens
technic
equip
reagent
dispos
cost
per
sampl
basic
pcr
usual
vari
approxim
us
inhous
develop
assay
cheapest
perform
cost
reduc
avoid
possibl
expens
procedur
csf
prepar
na
detect
use
assay
simultan
examin
multipl
virus
commerci
assay
advantag
includ
standardis
sometim
autom
jungkind
much
expens
gener
save
establish
rapid
diagnosi
often
overcom
cost
na
amplif
techniqu
ross
diagnosi
hse
csf
pcr
approach
evid
much
cheaper
brain
biopsi
seem
costeffect
also
compar
empir
initi
antivir
therapi
use
decis
analysi
model
use
csf
pcr
associ
better
outcom
hand
signific
save
acyclovir
result
higher
rate
correct
drug
discontinu
pcrneg
patient
teba
et
al
asept
mening
cost
save
seem
increas
adopt
pcr
test
procedur
compar
standard
practic
especi
year
season
characteris
higher
enteroviru
infect
preval
earli
demonstr
enteroviru
caus
agent
associ
reduc
request
diagnost
examin
durat
empir
antibiot
treatment
period
hospitalis
swingler
et
al
rice
et
al
marshal
et
al
ramer
et
al
major
drawback
na
amplif
techniqu
limit
standardis
differ
protocol
use
viru
differ
laboratori
refer
standard
evalu
assay
sensit
often
lack
make
difficult
compar
result
among
laboratori
saldanha
furthermor
test
csf
might
subject
laboratori
error
due
inaccur
test
valid
qualiti
reagent
equip
staff
train
garrett
help
obviat
problem
qualiti
control
qc
programm
carri
virus
infecti
agent
qc
assess
virus
respons
cn
infect
includ
enterovirus
jcv
perform
part
european
union
sponsor
qc
virolog
programm
van
vliet
et
al
muir
et
al
van
loon
et
al
weber
et
al
schloss
et
al
base
use
panel
consist
code
sampl
contain
known
amount
na
molecul
control
sampl
distribut
particip
laboratori
therein
test
blindli
analysi
report
result
commonli
reveal
substanti
differ
report
laboratori
especi
sampl
contain
low
amount
na
furthermor
signific
rate
fals
posit
result
observ
muir
et
al
schloss
et
al
hand
littl
relationship
gener
found
perform
use
inhous
rather
commerci
techniqu
array
na
amplif
techniqu
nowaday
applic
csf
order
establish
etiolog
diagnosi
viral
infect
cn
last
year
spectrum
clinic
condit
recognis
larg
expand
diagnost
reliabl
significantli
improv
quantit
method
provid
valuabl
addit
tool
clinic
manag
diseas
wherea
postamplif
techniqu
enabl
precis
characteris
viral
genom
follow
recoveri
csf
current
effort
aim
improv
diagnost
effici
molecular
techniqu
frequent
less
common
infect
also
increas
diagnost
speed
standardis
